Ipca Laboratories Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Ipca Laboratories Limited Pharmaceutical Export Portfolio Dataset — 39 Products, $304.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ipca Laboratories Limited — Pharmaceutical Exporter Profile (2026) | 39 Products, $304.9M Trade | TransData Nexus

Ipca Laboratories Limited

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $304.9M Total Trade · DGFT Verified

Ipca Laboratories Limited is an Indian pharmaceutical exporter with a total trade value of $304.9M across 39 products in 13 therapeutic categories. Based on 8,204 verified export shipments from Indian Customs (DGFT) records, Ipca Laboratories Limited is the #1 Indian exporter in 6 products including Allopurinol, Artemether, Artesunate. Top exports include Allopurinol ($30.8M), Artemether ($30.0M), Paracetamol ($23.3M).

Ipca Laboratories Limited — Export Portfolio & Destination Treemap

Ipca Laboratories Limited pharmaceutical export portfolio — 39 products across 13 therapeutic categories. Source: Indian Customs (DGFT).

Who is Ipca Laboratories Limited? — Company Overview & Market Position

Ipca Laboratories Limited, established on October 19, 1949, as The Indian Pharmaceutical Combine Association Limited, is a fully integrated Indian pharmaceutical company headquartered in Mumbai, Maharashtra. The company specializes in manufacturing and marketing over 350 formulations and 80 active pharmaceutical ingredients (APIs) across various therapeutic segments. Its products are sold in over 100 countries worldwide.

As of March 31, 2025, Ipca Laboratories reported a gross sales figure of ₹6,677.92 crore and a profit after tax of ₹650.76 crore. The company employs approximately 18,043 individuals, reflecting its substantial presence in the pharmaceutical industry. For more information, visit their official website at www.ipca.com.

What Does Ipca Laboratories Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Allopurinol$30.8M 2Artemether$30.0M

Product Portfolio — Top 30 by Export Value

Ipca Laboratories Limited exports 39 pharmaceutical products across 13 therapeutic categories. Market leader (#1 exporter) in 6 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Allopurinol	Lipid & Metabolism	$30.8M	616	6.2%	1
2	Artemether	Antimalarial & Antiparasitic	$30.0M	600	3.3%	1
3	Paracetamol	Analgesics & Antipyretics	$23.3M	466	6.5%	2
4	Amlodipine	Cardiovascular	$21.9M	438	0.2%	5
5	Artesunate	Antimalarial & Antiparasitic	$21.1M	422	12.3%	1
6	Chloroquine	Antimalarial & Antiparasitic	$19.1M	382	11.2%	2
7	Metformin	Diabetes & Endocrine	$17.1M	342	3.7%	4
8	Pantoprazole	Gastrointestinal	$16.2M	420	1.2%	6
9	Losartan	Cardiovascular	$9.5M	532	3.2%	9
10	Bisoprolol	Cardiovascular	$9.1M	513	10.8%	3
11	Atenolol	Cardiovascular	$8.3M	315	20.5%	1
12	Hydrochlorothiazide	Diuretics	$7.4M	264	1.8%	5
13	Gliclazide	Advanced Diabetes Medications	$7.3M	243	2.4%	5
14	Hydroxychloroquine	Antimalarial & Antiparasitic	$7.3M	146	5.2%	2
15	Cetirizine	Antihistamines & Allergy	$6.7M	134	3.8%	4
16	Enalapril	Cardiovascular	$6.2M	123	2.6%	2
17	Sertraline	CNS & Psychiatric	$6.2M	123	1.1%	8
18	Ibuprofen	Analgesics & Antipyretics	$6.0M	146	1.0%	13
19	Citalopram	CNS & Psychiatric	$6.0M	156	2.4%	10
20	Potassium	Nutritional Supplements	$5.3M	107	0.8%	15
21	Albendazole	Antimalarial & Antiparasitic	$5.2M	230	7.2%	3
22	Metoclopramide	Gastrointestinal	$5.1M	102	22.5%	1
23	Escitalopram	CNS & Psychiatric	$4.1M	108	2.1%	10
24	Simvastatin	Cardiovascular	$3.9M	77	3.1%	3
25	Glimepiride	Diabetes & Endocrine	$3.6M	90	4.7%	3
26	Furosemide	Diuretics	$3.4M	72	4.8%	3
27	Ondansetron	Gastrointestinal	$2.8M	80	2.3%	11
28	Propranolol	Cardiovascular	$2.8M	55	4.7%	1
29	Lisinopril	Cardiovascular	$2.7M	418	4.5%	3
30	Loperamide	Gastrointestinal	$2.1M	98	2.7%	4

Ipca Laboratories Limited exports 39 pharmaceutical products across 13 therapeutic categories with a total export value of $304.9M. The company is the #1 Indian exporter in 6 products: Allopurinol, Artemether, Artesunate, Atenolol, Metoclopramide and 1 more. The top category is Antimalarial & Antiparasitic (27.4% of portfolio), followed by Cardiovascular (21.5%), reflecting a diversified portfolio where the top 5 products account for only 41.7% of total value.

Showing top 30 of 39 products. Contact us for complete data.

Ipca Laboratories Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Ipca Laboratories operates 18 manufacturing units across India, producing both APIs and finished pharmaceutical formulations. These facilities are approved by various global regulatory authorities, including the UK Medicines and Healthcare products Regulatory Agency (MHRA), the European Directorate for the Quality of Medicines & HealthCare (EDQM), and the World Health Organization (WHO).

3Key Leadership

The leadership team at Ipca Laboratories includes:

Premchand Godha: Chairman and Executive Director
A.K. Jain: Managing Director and Chief Financial Officer
Anand T. Kusre: Independent Director
Pranay Godha: Managing Director
Prashant Godha: Executive Director
Manisha Premnath: Independent Director
Kamal Kishore Seth: Independent Director
Narendra Mairpady: Independent Director
Harish P. Kamath: Company Secretary and Compliance Officer

These executives play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Ipca Laboratories Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Ipca Laboratories has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has received approvals from the U.S. Food and Drug Administration (FDA), the UK's Medicines and Healthcare products Regulatory Agency (MHRA), and the European Directorate for the Quality of Medicines & HealthCare (EDQM). These certifications underscore Ipca's commitment to maintaining high-quality standards in its manufacturing processes.

2Emerging Markets

Ipca Laboratories has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has facilitated its entry into these regions, enabling access to a broader patient base and contributing to global health initiatives.

3Geographic Strategy

Ipca Laboratories demonstrates a diversified geographic strategy by operating in over 100 countries, including both developed and emerging markets. This global presence mitigates concentration risk and positions the company to leverage growth opportunities across various regions. The strategic direction focuses on expanding market share in existing territories while exploring new markets to enhance revenue streams.

Ipca Laboratories Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Ipca Laboratories has registered multiple facilities with the U.S. FDA, reflecting its commitment to meeting stringent regulatory standards. The company has received approvals for several Abbreviated New Drug Applications (ANDAs) and has filed Drug Master Files (DMFs) for various products. Inspection histories indicate compliance with FDA regulations, with no significant observations reported in recent years.

2WHO & EU GMP

The company's manufacturing facilities hold certifications from the World Health Organization (WHO) and the European Directorate for the Quality of Medicines & HealthCare (EDQM). These certifications affirm Ipca's adherence to Good Manufacturing Practices (GMP) and its commitment to producing high-quality pharmaceutical products.

3CDSCO & Indian Regulatory

Ipca Laboratories possesses manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and approvals from various state drug controllers in India. The company has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating its international trade operations.

Ipca Laboratories Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Ipca Laboratories faces competition from other pharmaceutical companies operating in similar therapeutic categories. While specific market share data is not available, the company's diverse product portfolio and global presence position it competitively in the market. Continuous innovation and adherence to quality standards are essential for maintaining its competitive edge.

2Key Differentiators

Ipca Laboratories' key differentiators include its extensive product portfolio, comprising over 350 formulations and 80 APIs, and its global manufacturing capabilities with 18 units across India. The company's commitment to quality is evidenced by certifications from regulatory bodies such as the FDA, MHRA, and EDQM. Additionally, its focus on research and development in chemical research, analytical research, biosimilar development, bio-processing, and new drug discovery enhances its competitive advantage.

3Strategic Position

Ipca Laboratories maintains a strategic focus on both generics and specialty pharmaceuticals, with a significant emphasis on antimalarial and antiparasitic drugs. The company's future outlook includes expanding its presence in emerging markets and enhancing its research and development capabilities to drive innovation and growth.

Buyer Due Diligence Brief — Evaluating Ipca Laboratories Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Ipca Laboratories has a strong track record in pharmaceutical manufacturing, with a diverse product portfolio and a global presence. The company's export volume and consistency are supported by its adherence to international quality standards and regulatory approvals. Reliability indicators include certifications from the FDA, MHRA, and EDQM, as well as a favorable inspection history.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm through the FDA's official website or contact Ipca Laboratories directly.
WHO-GMP Certification: Verify via the WHO's official website or request documentation from Ipca Laboratories.
EU GMP Certification: Check the European Medicines Agency (EMA) website or obtain confirmation from Ipca Laboratories.

Frequently Asked Questions — Ipca Laboratories Limited

How many pharmaceutical products does Ipca Laboratories Limited export from India?

Ipca Laboratories Limited exports 39 pharmaceutical products across 13 therapeutic categories. The top exports are Allopurinol ($30.8M), Artemether ($30.0M), Paracetamol ($23.3M), Amlodipine ($21.9M), Artesunate ($21.1M). Total export value is $304.9M.

What is Ipca Laboratories Limited's total pharmaceutical export value?

Ipca Laboratories Limited's total pharmaceutical export value is $304.9M, based on 8,204 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Ipca Laboratories Limited the #1 Indian exporter?

Ipca Laboratories Limited is the #1 Indian exporter in 6 products: Allopurinol (6.2% market share), Artemether (3.3% market share), Artesunate (12.3% market share), Atenolol (20.5% market share), Metoclopramide (22.5% market share), Propranolol (4.7% market share).

What therapeutic categories does Ipca Laboratories Limited cover?

Ipca Laboratories Limited exports across 13 therapeutic categories. The largest are Antimalarial & Antiparasitic (27.4%, 7 products), Cardiovascular (21.5%, 10 products), Lipid & Metabolism (10.1%, 1 products).

Get Full Ipca Laboratories Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.